The University of Southampton
University of Southampton Institutional Repository

FebriDx for C-reactive protein and myxovirus resistance protein A testing. NICE Medtech Innovation briefing

FebriDx for C-reactive protein and myxovirus resistance protein A testing. NICE Medtech Innovation briefing
FebriDx for C-reactive protein and myxovirus resistance protein A testing. NICE Medtech Innovation briefing
• The technology described in this briefing is FebriDx. It is a rapid dual marker immunoassay test.
The test detects raised levels of C-reactive protein (CRP) and myxovirus resistance protein A
(MxA) in peripheral whole blood. The test is done at the point of care and gives results in
10 minutes.
• The innovative aspects are that the FebriDx test measures MxA, a marker for viral infection, as
well as CRP. This helps clinicians to differentiate between bacterial and viral respiratory tract
infections.
• The intended place in therapy would be in primary or secondary care, to help guide the
appropriate use of antibiotics for people with acute febrile respiratory tract infections. It could
also help with early detection of viral infections, such as COVID-19.
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f

Clark, Tristan (2020) FebriDx for C-reactive protein and myxovirus resistance protein A testing. NICE Medtech Innovation briefing. 15 pp .

Record type: Conference or Workshop Item (Paper)

Abstract

• The technology described in this briefing is FebriDx. It is a rapid dual marker immunoassay test.
The test detects raised levels of C-reactive protein (CRP) and myxovirus resistance protein A
(MxA) in peripheral whole blood. The test is done at the point of care and gives results in
10 minutes.
• The innovative aspects are that the FebriDx test measures MxA, a marker for viral infection, as
well as CRP. This helps clinicians to differentiate between bacterial and viral respiratory tract
infections.
• The intended place in therapy would be in primary or secondary care, to help guide the
appropriate use of antibiotics for people with acute febrile respiratory tract infections. It could
also help with early detection of viral infections, such as COVID-19.

Text
NICE Medtech innovation briefing FebriDx 2020 - Version of Record
Restricted to Repository staff only
Request a copy

More information

Published date: 26 August 2020

Identifiers

Local EPrints ID: 449303
URI: http://eprints.soton.ac.uk/id/eprint/449303
PURE UUID: 1173b53e-385b-4c02-accc-5fdcf30ea0ca
ORCID for Tristan Clark: ORCID iD orcid.org/0000-0001-6026-5295

Catalogue record

Date deposited: 24 May 2021 16:30
Last modified: 13 Dec 2021 03:13

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×